Summary

KEY FINDINGS
The India retinal imaging devices market size is valued at $184.51 million as of 2026 and is expected to reach $418.89 million by 2034, progressing with a CAGR of 10.79% during the forecast years, 2026-2034.

MARKET INSIGHTS
India represents one of the fastest-growing markets for retinal imaging devices globally, driven by an enormous diabetic population, expanding private healthcare infrastructure, and increasing government focus on preventable blindness initiatives. The nation harbors approximately one-fifth of the world's adults with diabetes, creating unprecedented demand for systematic retinal screening programs across urban and rural healthcare facilities.
According to research published in The Lancet Global Health, the estimated national prevalence of diabetic retinopathy stands at 12.5% among people with diabetes, with vision-threatening diabetic retinopathy affecting 4.0% of this population, translating to approximately 3 million individuals aged 40 years and older requiring urgent medical attention. Moreover, India's burgeoning middle class increasingly seeks quality eye care services, supporting the expansion of specialized ophthalmology chains and diagnostic centers throughout metropolitan areas and tier-II cities.
The market benefits from growing domestic manufacturing capabilities, with Indian companies developing cost-effective retinal imaging solutions specifically adapted to local infrastructure constraints and budget limitations. Additionally, government initiatives under the National Programme for Control of Blindness and Visual Impairment prioritize diabetic retinopathy screening, allocating resources for equipment procurement and workforce training throughout public health facilities.
Furthermore, teleophthalmology programs gain traction as viable solutions for extending retinal screening access to underserved rural populations, where traditional eye care infrastructure remains inadequate despite high disease prevalence. Consequently, manufacturers offering robust, low-maintenance retinal imaging devices suitable for high-volume settings at competitive price points capture substantial market share throughout India's diverse and rapidly evolving healthcare landscape.

SEGMENTATION ANALYSIS
The India retinal imaging devices market is segmented into device, application, and indication. The device segment is further categorized into optical coherence tomography (OCT) devices, fluorescein angiography devices, fundus cameras, retinal ultrasound imaging systems, ultra widefield retinal imaging devices, widefield retinal imaging devices, and other devices.
Fundus cameras, under the device segment, are essential within India's retinal imaging market due to their optimal balance between clinical utility, affordability, and operational simplicity suited to diverse healthcare settings. Healthcare providers throughout India deploy non-mydriatic fundus cameras extensively for diabetic retinopathy screening programs, eliminating the need for pupil dilation that would otherwise require additional personnel, time, and patient cooperation.
These portable retinal photography systems enable rapid image capture in primary care clinics, diabetes centers, mobile screening camps, and community health facilities lacking specialized ophthalmology infrastructure. Moreover, fundus cameras require minimal training for operation compared to advanced optical coherence tomography systems, addressing India's shortage of specialized ophthalmic technicians, particularly acute in rural and semi-urban areas.
The segment benefits from the growing availability of affordable fundus imaging equipment from domestic manufacturers like Forus Health, which develops solutions specifically designed for Indian market conditions, including variable power supply, hot and humid environments, and high patient volumes. Additionally, fundus cameras integrate seamlessly with emerging artificial intelligence-powered diabetic retinopathy detection algorithms, enabling automated preliminary screening that reduces ophthalmologist workload while maintaining diagnostic accuracy.
Healthcare facilities appreciate the technology's cost-effectiveness, with entry-level non-mydriatic fundus cameras priced substantially lower than spectral-domain OCT systems, making them accessible to smaller clinics and government primary health centers operating under tight budget constraints. Furthermore, fundus photography generates permanent image records suitable for remote grading through teleophthalmology networks, connecting rural screening sites with urban retina specialists who provide expert consultation without requiring patient travel.
Private eye hospital chains like Aravind Eye Care System and Dr. Agarwal's Eye Hospital deploy fundus cameras across their multi-location networks, standardizing diabetic retinopathy screening protocols while building comprehensive databases for research and quality monitoring. The segment also witnesses increasing adoption of hybrid fundus cameras capable of both mydriatic and non-mydriatic imaging modes, providing flexibility for comprehensive examinations when pupil dilation becomes clinically necessary.
Consequently, fundus cameras remain a primary retinal diagnostic tool throughout India's healthcare system, balancing technological sophistication with practical considerations of cost, ease of use, and suitability for mass screening applications essential to addressing the nation's enormous diabetic eye disease burden.

COMPETITIVE INSIGHTS
Some of the top players operating in the India retinal imaging devices market include Canon Inc, Carl Zeiss Meditec AG, Forus Health Pvt Ltd, Heidelberg Engineering GmbH, Kowa Company Ltd, Nidek Co Ltd, Optos PLC, Topcon Corporation, etc.
Forus Health Pvt Ltd stands as India's leading domestic manufacturer of ophthalmic diagnostic equipment, headquartered in Bengaluru, Karnataka, with strong pan-India presence and expanding international operations throughout Asia, Africa, and Latin America. The company specializes in affordable, robust retinal imaging solutions specifically engineered for emerging market conditions, particularly its flagship 3nethra series of portable fundus cameras and screening devices.
Moreover, Forus Health's product portfolio encompasses comprehensive retinal diagnostic platforms, including the 3nethra classic non-mydriatic fundus camera offering true color imaging without pupil dilation, the 3nethra neo compact imaging system designed for mobile screening programs, handheld retinal cameras for bedside examinations, and integrated artificial intelligence software for automated diabetic retinopathy detection.
Additionally, Forus Health pioneered India's first indigenously developed swept-source optical coherence tomography device, demonstrating technological capabilities matching international competitors while maintaining price points accessible to Indian healthcare providers. The company serves diverse customer segments throughout India, including government hospitals participating in national blindness control programs, private eye hospital chains like Aravind Eye Care and Sankara Nethralaya, diabetes care centers, optical retail outlets offering comprehensive eye examinations, and corporate wellness programs conducting employee health screenings.

COMPANY PROFILES
1. CANON INC
2. CARL ZEISS MEDITEC AG
3. FORUS HEALTH PVT LTD
4. HEIDELBERG ENGINEERING GMBH
5. KOWA COMPANY LTD
6. NIDEK CO LTD
7. OPTOS PLC
8. TOPCON CORPORATION

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & FORECAST
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. INDIA SHOWS STRONG DEMAND FOR COST-EFFECTIVE RETINAL IMAGING DEVICES ACROSS PUBLIC AND PRIVATE HEALTHCARE
2.5.2. FUNDUS CAMERAS AND SD-OCT SYSTEMS ARE THE MOST WIDELY DEPLOYED DUE TO BALANCED COST AND CLINICAL UTILITY
2.5.3. PRIVATE EYE HOSPITAL CHAINS PLAY A CENTRAL ROLE IN TECHNOLOGY ADOPTION AND DIFFUSION
2.5.4. RURAL MARKETS REMAIN SIGNIFICANTLY UNDERSERVED DESPITE HIGH DISEASE PREVALENCE
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. HIGH AND GROWING DIABETIC POPULATION IS DRIVING LARGE-SCALE RETINAL SCREENING NEEDS
3.1.2. EXPANSION OF EYE CARE CHAINS AND DIAGNOSTIC CENTERS IS SUPPORTING EQUIPMENT INSTALLATIONS
3.1.3. GOVERNMENT PROGRAMS FOCUSED ON PREVENTABLE BLINDNESS ARE IMPROVING SCREENING INFRASTRUCTURE
3.1.4. INCREASING THE AFFORDABILITY OF ENTRY-LEVEL AND LOCALLY ADAPTED DEVICES IS BOOSTING PENETRATION
3.2. KEY RESTRAINTS
3.2.1. CAPITAL COST SENSITIVITY LIMITS ADOPTION OF HIGH-END IMAGING SYSTEMS
3.2.2. SHORTAGE OF TRAINED OPHTHALMOLOGISTS AND TECHNICIANS AFFECTS DEVICE UTILIZATION
3.2.3. PUBLIC HOSPITAL PROCUREMENT DELAYS SLOW MARKET EXPANSION
3.2.4. INFRASTRUCTURE LIMITATIONS IN TIER II AND TIER III CITIES RESTRICT ADVANCED DEPLOYMENTS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. STRONG SHIFT TOWARD PORTABLE AND HANDHELD RETINAL IMAGING DEVICES
4.1.2. INCREASING USE OF TELE-OPHTHALMOLOGY AND REMOTE SCREENING MODELS
4.1.3. RISING INTEREST IN AI-BASED DIABETIC RETINOPATHY DETECTION TO SUPPORT MASS SCREENING
4.1.4. PREFERENCE FOR ROBUST LOW-MAINTENANCE DEVICES SUITED FOR HIGH-VOLUME SETTINGS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR INDIA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. RAW MATERIAL SUPPLIERS
4.6.2. OPTICAL COMPONENTS
4.6.3. DEVICE MANUFACTURING
4.6.4. SOFTWARE DEVELOPMENT
4.6.5. DISTRIBUTION CHANNELS
4.6.6. HOSPITALS AND CLINICS
4.6.7. AFTERSALES SUPPORT
4.7. KEY BUYING CRITERIA
4.7.1. IMAGE RESOLUTION
4.7.2. CLINICAL ACCURACY
4.7.3. EASE OF USE
4.7.4. TOTAL COST OWNERSHIP
4.8. REGULATORY FRAMEWORK
5. RETINAL IMAGING DEVICES MARKET BY DEVICE
5.1. OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES
5.1.1. SPECTRAL-DOMAIN OCT (SD-OCT)
5.1.2. SWEPT-SOURCE OCT (SS-OCT)
5.1.3. HANDHELD OCT
5.2. FLUORESCEIN ANGIOGRAPHY DEVICES
5.3. FUNDUS CAMERAS
5.3.1. MYDRIATIC FUNDUS CAMERAS
5.3.2. NON-MYDRIATIC FUNDUS CAMERAS
5.3.3. HYBRID FUNDUS CAMERAS
5.3.4. ROP FUNDUS CAMERAS
5.4. RETINAL ULTRASOUND IMAGING SYSTEMS
5.4.1. OPHTHALMIC A-SCAN ULTRASOUND
5.4.2. OPHTHALMIC B-SCAN ULTRASOUND
5.4.3. OPHTHALMIC ULTRASOUND BIOMICROSCOPES
5.4.4. OPHTHALMIC PACHYMETERS
5.5. ULTRA WIDEFIELD RETINAL IMAGING DEVICES
5.6. WIDEFIELD RETINAL IMAGING DEVICES
5.7. OTHER DEVICES
6. RETINAL IMAGING DEVICES MARKET BY APPLICATION
6.1. DISEASE DIAGNOSIS
6.2. TREATMENT MONITORING
6.3. RESEARCH AND DEVELOPMENT
7. RETINAL IMAGING DEVICES MARKET BY INDICATION
7.1. DIABETIC RETINOPATHY
7.2. AGE-RELATED MACULAR DEGENERATION (AMD)
7.3. GLAUCOMA
7.4. RETINAL VEIN OCCLUSION
7.5. OTHER INDICATIONS
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.1.4. BUSINESS EXPANSIONS & DIVESTITURES
8.2. COMPANY PROFILES
8.2.1. CANON INC
8.2.1.1. COMPANY OVERVIEW
8.2.1.2. PRODUCT LIST
8.2.1.3. STRENGTHS & CHALLENGES
8.2.2. CARL ZEISS MEDITEC AG
8.2.2.1. COMPANY OVERVIEW
8.2.2.2. PRODUCT LIST
8.2.2.3. STRENGTHS & CHALLENGES
8.2.3. FORUS HEALTH PVT LTD
8.2.3.1. COMPANY OVERVIEW
8.2.3.2. PRODUCT LIST
8.2.3.3. STRENGTHS & CHALLENGES
8.2.4. HEIDELBERG ENGINEERING GMBH
8.2.4.1. COMPANY OVERVIEW
8.2.4.2. PRODUCT LIST
8.2.4.3. STRENGTHS & CHALLENGES
8.2.5. KOWA COMPANY LTD
8.2.5.1. COMPANY OVERVIEW
8.2.5.2. PRODUCT LIST
8.2.5.3. STRENGTHS & CHALLENGES
8.2.6. NIDEK CO LTD
8.2.6.1. COMPANY OVERVIEW
8.2.6.2. PRODUCT LIST
8.2.6.3. STRENGTHS & CHALLENGES
8.2.7. OPTOS PLC
8.2.7.1. COMPANY OVERVIEW
8.2.7.2. PRODUCT LIST
8.2.7.3. STRENGTHS & CHALLENGES
8.2.8. TOPCON CORPORATION
8.2.8.1. COMPANY OVERVIEW
8.2.8.2. PRODUCT LIST
8.2.8.3. STRENGTHS & CHALLENGES


LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - RETINAL IMAGING DEVICES
TABLE 2: MARKET BY DEVICE, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 3: MARKET BY DEVICE, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 4: MARKET BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 5: MARKET BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 6: MARKET BY FUNDUS CAMERAS, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 7: MARKET BY FUNDUS CAMERAS, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 8: MARKET BY RETINAL ULTRASOUND IMAGING SYSTEMS, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 9: MARKET BY RETINAL ULTRASOUND IMAGING SYSTEMS, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 10: MARKET BY APPLICATION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 11: MARKET BY APPLICATION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 12: MARKET BY INDICATION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 13: MARKET BY INDICATION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 14: KEY PLAYERS OPERATING IN THE INDIAN MARKET
TABLE 15: LIST OF MERGERS & ACQUISITIONS
TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 18: LIST OF BUSINESS EXPANSIONS & DIVESTITURES


LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR INDIA
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: KEY BUYING CRITERIA
FIGURE 8: SEGMENT GROWTH POTENTIAL, BY DEVICE, IN 2025
FIGURE 9: OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 10: SEGMENT GROWTH POTENTIAL, BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, IN 2025
FIGURE 11: SPECTRAL-DOMAIN OCT (SD-OCT) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 12: SWEPT-SOURCE OCT (SS-OCT) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 13: HANDHELD OCT MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 14: FLUORESCEIN ANGIOGRAPHY DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 15: FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 16: SEGMENT GROWTH POTENTIAL, BY FUNDUS CAMERAS, IN 2025
FIGURE 17: MYDRIATIC FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 18: NON-MYDRIATIC FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 19: HYBRID FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 20: ROP FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 21: RETINAL ULTRASOUND IMAGING SYSTEMS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 22: SEGMENT GROWTH POTENTIAL, BY RETINAL ULTRASOUND IMAGING SYSTEMS, IN 2025
FIGURE 23: OPHTHALMIC A-SCAN ULTRASOUND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 24: OPHTHALMIC B-SCAN ULTRASOUND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 25: OPHTHALMIC ULTRASOUND BIOMICROSCOPES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 26: OPHTHALMIC PACHYMETERS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 27: ULTRA WIDEFIELD RETINAL IMAGING DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 28: WIDEFIELD RETINAL IMAGING DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 29: OTHER DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 30: SEGMENT GROWTH POTENTIAL, BY APPLICATION, IN 2025
FIGURE 31: DISEASE DIAGNOSIS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 32: TREATMENT MONITORING MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 33: RESEARCH AND DEVELOPMENT MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 34: SEGMENT GROWTH POTENTIAL, BY INDICATION, IN 2025
FIGURE 38: DIABETIC RETINOPATHY MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 35: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 36: GLAUCOMA MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 37: RETINAL VEIN OCCLUSION MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 38: OTHER INDICATIONS MARKET SIZE, 2026-2034 (IN $ MILLION)